

Carmine Carbone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/80761/publications.pdf>

Version: 2024-02-01

52
papers

2,159
citations

201385

27
h-index

253896

43
g-index

52
all docs

52
docs citations

52
times ranked

3975
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
2	Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview. <i>Seminars in Oncology</i> , 2021, 48, 95-105.	0.8	11
3	Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go. <i>Journal of Personalized Medicine</i> , 2021, 11, 216.	1.1	44
4	Molecular alterations in basal cell carcinoma subtypes. <i>Scientific Reports</i> , 2021, 11, 13206.	1.6	19
5	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 351-360.	1.1	7
6	The impact of COVID-19 on pancreatic cancer research and the path forward. <i>Gastroenterology</i> , 2021, 161, 1758-1763.	0.6	8
7	Conversion therapy with encorafenib and cetuximab for chemo-refractory BRAF V600E- mutated liver-limited colorectal cancer metastasis: the first case report.. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	1
8	Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. , 2021, 9, e002876.		25
9	Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. <i>Frontiers in Medicine</i> , 2021, 8, 793144.	1.2	8
10	Small Molecule Inhibitors of Microenvironmental Wnt/ β 2-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2696.	1.7	14
11	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6386.	1.8	15
12	Systemic profile of immune factors in an elderly Italian population affected by chronic strongyloidiasis. <i>Parasites and Vectors</i> , 2020, 13, 515.	1.0	4
13	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 308.	1.8	8
14	Gut microbiome, big data and machine learning to promote precision medicine for cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 635-648.	8.2	172
15	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients's Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.	1.2	7
16	Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion. <i>Blood</i> , 2020, 135, 2071-2084.	0.6	44
17	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , 2019, 11, 1141.	1.7	71
18	Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. <i>Scientific Reports</i> , 2019, 9, 12286.	1.6	27

#	ARTICLE	IF	CITATIONS
19	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019, 11, 1525.	1.7	28
20	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
21	Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1405-1417.	1.9	18
22	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	39
23	The Vasculopathy in the Bone Marrow Microenvironment of Humanized Sickle Cell Mice Is Reversible By Blood Transfusion. <i>Blood</i> , 2019, 134, 2256-2256.	0.6	0
24	Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 357-370.	1.5	6
25	Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. <i>International Journal of Obesity</i> , 2018, 42, 334-343.	1.6	31
26	Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 1-14.	2.5	33
27	Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. <i>Nature Communications</i> , 2018, 9, 5193.	5.8	45
28	Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3331.	1.8	38
29	Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 431.	1.8	142
30	MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. <i>Anticancer Research</i> , 2018, 38, 1937-1946.	0.5	27
31	A circulating T _H 2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. <i>Oncolmmunology</i> , 2017, 6, e1322242.	2.1	39
32	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4312-4322.	3.2	41
33	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2575-2583.	3.2	16
34	TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. <i>Drug Resistance Updates</i> , 2017, 33-35, 36-42.	6.5	36
35	Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. <i>Amino Acids</i> , 2017, 49, 517-528.	1.2	9
36	EMT and Treatment Resistance in Pancreatic Cancer. <i>Cancers</i> , 2017, 9, 122.	1.7	105

#	ARTICLE	IF	CITATIONS
37	Combined inhibition of IL1, CXCR1/2, and TGF β 2 signaling pathways modulates in-vivo resistance to anti-VEGF treatment. <i>Anti-Cancer Drugs</i> , 2016, 27, 29-40.	0.7	29
38	Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000620.	0.5	5
39	An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 6164-6175.	3.2	65
40	Resistance to ALK Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 147-163.	0.1	1
41	TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 878-885.	2.9	40
42	An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. <i>Oncotarget</i> , 2015, 6, 13822-13834.	0.8	47
43	Current Strategies to Overcome Resistance to ALK-Inhibitor Agents. <i>Current Drug Metabolism</i> , 2015, 16, 585-596.	0.7	13
44	Toll-Like Receptor 9 Agonists for Cancer Therapy. <i>Biomedicines</i> , 2014, 2, 211-228.	1.4	31
45	Tissue transglutaminase: a new target to reverse cancer drug resistance. <i>Amino Acids</i> , 2013, 44, 63-72.	1.2	52
46	Rationale and clinical use of multitargeting anticancer agents. <i>Current Opinion in Pharmacology</i> , 2013, 13, 536-542.	1.7	29
47	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. <i>Frontiers in Pharmacology</i> , 2013, 4, 56.	1.6	79
48	Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. <i>Cell Death and Disease</i> , 2013, 4, e641-e641.	2.7	57
49	NF- κ B as a target for pancreatic cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S1-S10.	1.5	81
50	Anti-VEGF Treatmentâ€“Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype. <i>Clinical Cancer Research</i> , 2011, 17, 5822-5832.	3.2	86
51	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. <i>Journal of Cellular Physiology</i> , 2011, 226, 2378-2390.	2.0	139
52	Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1190-1204.	3.0	137